Liposomal amphotericin B for complicated visceral leishmaniasis (kala‐azar) in eastern Sudan: how effective is treatment for this neglected disease?

Abstract

AmBisome appears to be effective for initial cure of VL and the drug seems safe, but is expensive (400 USD/treatment). Sustained mechanisms to allow improved access of this expensive drug particularly in East Africa are urgently needed. Relapses and losses to follow-up require specific investigation.